{"id":86663,"date":"2025-08-22T04:50:06","date_gmt":"2025-08-22T04:50:06","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/86663\/"},"modified":"2025-08-22T04:50:06","modified_gmt":"2025-08-22T04:50:06","slug":"the-hbsag-hbv-dna-ratios-potential-for-predicting-disease-progression","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/86663\/","title":{"rendered":"The HBsAg\/HBV DNA ratio&#8217;s potential for predicting disease progression"},"content":{"rendered":"<p>Patients with chronic hepatitis B virus (HBV) infection in the immune-tolerant phase may still experience hepatic inflammation and disease progression, and could benefit from early antiviral treatment.<\/p>\n<p>This study aimed to investigate changes in the cumulative hepatitis B surface <a href=\"https:\/\/www.news-medical.net\/health\/What-is-an-Antigen.aspx\" class=\"linked-term\" rel=\"nofollow noopener\" target=\"_blank\">antigen<\/a> (HBsAg)\/HBV DNA ratio in immune-tolerant patients during the transition to the immune-active phase, and to evaluate its potential in predicting the risk of disease progression.<\/p>\n<p>Methods<\/p>\n<p>This longitudinal study included 127 untreated immune-tolerant patients, who were followed for up to 10 years. An independent cohort of 109 subjects was retrospectively enrolled for external validation. The relationship between the cumulative HBsAg\/HBV DNA ratio and the duration of immune tolerance or transition to the immune-active phase was examined. The predictive value of the ratio was assessed and validated.<\/p>\n<p>Results<\/p>\n<p>The relationship between the cumulative HBsAg\/HBV DNA ratio and disease progression risk showed a non-linear pattern: below a ratio of 1.791, the risk of disease progression decreased rapidly as the ratio increased; above 1.791, the risk plateaued. The area under the curve for predicting disease progression was 0.67, 0.64, and 0.85 for cumulative HBsAg, HBV DNA, and the HBsAg\/HBV DNA ratio, respectively.<\/p>\n<p>Multivariable Cox regression analysis revealed the cumulative HBsAg\/HBV DNA ratio as an independent predictor of disease progression, with higher ratios associated with a lower risk. Prediction models incorporating this ratio were developed and externally validated, demonstrating strong performance and clinical utility.<\/p>\n<p>Conclusions<\/p>\n<p>This study identifies the cumulative HBsAg\/HBV DNA ratio as an independent predictor of immune tolerance duration in patients with chronic HBV infection. A lower ratio correlates with an increased risk of transition from the immune-tolerant phase to the immune-active phase, particularly when it falls below 1.791, at which point the risk of disease progression increases sharply.<\/p>\n<p>Additionally, patients aged \u226530 years face a notably higher risk of disease progression, underscoring the need for vigilant monitoring in this population. These findings have important implications for the proactive management of immune-tolerant patients. Early detection of disease progression and timely antiviral treatment may ultimately improve clinical outcomes and societal benefits for individuals suffering from chronic HBV infection.<\/p>\n<p>Source:<\/p>\n<p>Journal reference:<\/p>\n<p>Zeng, D., et al. (2025). Cumulative Hepatitis B Surface Antigen\/Hepatitis B Virus DNA Ratio in Immune-tolerant Hepatitis B Patients: A 10-year Follow-up Study. Journal of Clinical and Translational Hepatology. <a href=\"http:\/\/dx.doi.org\/10.14218\/JCTH.2025.00205\" rel=\"noopener nofollow\" target=\"_blank\">doi.org\/10.14218\/JCTH.2025.00205<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Patients with chronic hepatitis B virus (HBV) infection in the immune-tolerant phase may still experience hepatic inflammation and&hellip;\n","protected":false},"author":2,"featured_media":4961,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[40440,64,63,1729,1115,64690,137,48341,64688,64689,1731,1624,1726,337,7277],"class_list":["post-86663","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-antigen","tag-au","tag-australia","tag-chronic","tag-dna","tag-hbv","tag-health","tag-hepatitis","tag-hepatitis-b","tag-hepatitis-b-virus","tag-hepatology","tag-inflammation","tag-liver","tag-research","tag-virus"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/86663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=86663"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/86663\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/4961"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=86663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=86663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=86663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}